IRadimed Corp (IRMD) company profile
Close on Nov 17, 2026Market cap $1.07BP/E 44.6Yield –
About IRadimed
Surgical & Medical Instruments & Apparatus, SIC 3841
IRADIMED CORPORATION develops, manufactures, and sells medical devices, disposables, and services engineered for magnetic resonance imaging environments. Its core offerings include the MRidium 3870 and MRidium 3860+ non-magnetic intravenous infusion pump systems, proprietary single-use intravenous tubing sets, and the IRadimed 3880 patient vital signs monitoring system. The company also supplies ferromagnetic detection devices, replacement accessories, and maintenance contracts. Its products serve hospitals and acute care facilities worldwide, particularly radiology departments, intensive care units, emergency rooms, and surgical centers requiring continuous medication delivery and patient monitoring during scans.
The company distributes products in the United States and roughly 80 foreign countries. Within the United States, commercial operations rely on a direct sales force consisting of 29 field representatives, four regional sales directors, and ten clinical application specialists. Outside the domestic market, it markets products through third-party distributors. Cumulatively, the business has distributed roughly 13,098 infusion pump channels and 3,397 vital signs monitoring systems. The provided report does not state the location of the corporate headquarters.
Summary of the business section of IRadimed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IRadimed Corp
- Founded
- 1992
- Headquarters
- Orlando, FL
- Address
- 12705 Ingenuity Drive 32826
- Phone
- (407) 677-8022
- Website
- iradimed.com
- Employees
- 166, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, Orlando, Florida
Stock & identifiers
- Ticker
- IRMD
- Exchange
- Nasdaq
- IPO date
- Jul 16, 2014
- Shares outstanding
- 13M, Oct 30, 2026
- Public float
- $480.86M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1325618
- CUSIP
- 46266A109
- ISIN
- US46266A1097
- FIGI
- BBG006NM92X2
- Share class FIGI
- BBG006NM92Y1
- LEI
- 549300YVHWP0YJ1YW816
- EIN
- 73-1408526
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Roger E. Susi | CEO, President, Chairman, Director | 4,387,950 |
| John Glenn | CFO | 14,256 |
| Jeff Chiprin | Chief Commercial Officer | 996 |
| Joe E. Kiani | Director | 698 |
| Monty K. Allen | Director | 19,986 |
| Hilda Frederique Scharen-Guivel | Director | 5,598 |
| James B. Hawkins | Director | 29,647 |
| Anthony Vuoto | Director | 17,181 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $780.60K | $780.60K | $569.68K | $368 | – |
| FY2024 | $689.58K | $689.58K | $825.79K | $205 | – |
| FY2023 | $642.57K | $642.57K | $932.30K | $175 | – |
| FY2022 | $586.04K | $586.04K | $666.73K | $63 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Roger Susi President and Chief Executive Officer | $385.60K | $395.00K | – | $780.60K | +13% |
| Jeffrey Chiprin Chief Commercial Officer | $205.00K | $228.00K | $96.36K | $529.36K | +36% |
| John Glenn Chief Financial Officer | $378.93K | $200.00K | $31.06K | $609.99K | -52% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 16, 2014
- Offer price
- $6.25
- Securities offered
- 2,016,000
- Gross proceeds
- $12.60M
- Exchange
- Nasdaq
- First trading day
- Jul 16, 2014
- First-day close
- $9.90+58.4%
- Lock-up ends (est.)
- Jan 12, 2015
“The initial public offering price is $6.25 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 166 full-time employees, including 55 in manufacturing and service, 68 in sales, marketing and customer support services, 14 in regulatory affairs and quality assurance, 14 in finance and administration and 15 in research and development.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 7, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 16, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 10, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?